Heather Fean
Adult Health · Berlin, NJNPI 1538379771
Payments from drug & device makers
Across 221 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$533
- Novo Nordisk$450
- AbbVie$423
- AstraZeneca$323
- Lilly USA, LLC$304
- Exact Sciences$202
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 28 | $533 |
| Novo Nordisk | 27 | $450 |
| AbbVie | 44 | $423 |
| AstraZeneca | 17 | $323 |
| Lilly USA, LLC | 20 | $304 |
| Exact Sciences | 12 | $202 |
| GSK | 13 | $196 |
| Pfizer | 12 | $193 |
| Boehringer Ingelheim | 13 | $187 |
| Lundbeck LLC | 4 | $70 |
| Mannkind Corporation | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 4 | $58 |
| Johnson & Johnson | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Novartis | 3 | $47 |
| Dexcom, Inc. | 2 | $35 |
| Merck | 2 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Amgen | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Meridian Bioscience Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Abbott | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
How this compares
$3,402 in reported general payments places this provider in the 85th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $52,263 |
| OzempicSemaglutide | 28 | $50,867 |
| MounjaroTirzepatide | 36 | $42,183 |
| EliquisApixaban | 28 | $32,899 |
| JanuviaSitagliptin Phosphate | 14 | $21,236 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,877 |
| MyrbetriqMirabegron | 13 | $13,210 |
| EntrestoSacubitril/Valsartan | 14 | $12,943 |
| XareltoRivaroxaban | 11 | $12,069 |
| FarxigaDapagliflozin Propanediol | 14 | $10,863 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $4,847 |
| Rosuvastatin Calcium | 242 | $4,362 |
| Atorvastatin Calcium | 220 | $3,027 |
| Losartan Potassium | 223 | $2,481 |
| Amlodipine Besylate | 298 | $2,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $187 | $52,26332 claims |
| Novo NordiskOzempic | $450 | $50,86728 claims |
| Lilly USA, LLCMounjaro | $304 | $42,18336 claims |
| PfizerEliquis | $193 | $32,89928 claims |
| MerckJanuvia | $32 | $21,23614 claims |
| GSKTrelegy Ellipta | $196 | $16,87721 claims |
| NovartisEntresto | $47 | $12,94314 claims |
| Johnson & JohnsonXarelto | $51 | $12,06911 claims |
| AstraZenecaFarxiga | $323 | $10,86314 claims |
| AbbVieSynthroid | $423 | $1,19512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Berlin
- June HalperHackensack$458K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.